ClinicalTrials.gg

Program

bafisontamab

Also written as “EMB-01”, “EMB-01 1600 mg administered once weekly throughout the study” and “EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter”.

Its studies are mostly in Colorectal Neoplasms · Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Neoplasms · Smoking Cessation, led by 2 companies.

Furthest: phase 3, since Dec 26, 20185 company-led studies, 4 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai EpimAb Biotherapeutics44 open or runningphase 2since Dec 26, 2018Dec 26, 2018Dec 30, 2027phase 2 · NCT07314294
Rose Research Center10 open or runningphase 3since Oct 5, 2020Oct 5, 2020none ahead

Also a collaborator on its studies: labcorp-corporation-of-america-holdings-inc, covance and embera-neurotherapeutics-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 26, 2018First study: phase 2 study in NeoplasmsNew to Shanghai EpimAb BiotherapeuticsShanghai EpimAb Biotherapeutics · NCT03797391 · 186 planned · United States, China
  2. Oct 5, 2020Rose Research Center's first study: phase 3 study in Smoking CessationNew to Rose Research CenterRose Research Center · NCT04868253 · 25 enrolled · United States
  3. Nov 3, 2021Phase 2 study in NeoplasmsShanghai EpimAb Biotherapeutics · NCT05176665 · 152 planned · United States, China
  4. Jun 28, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungShanghai EpimAb Biotherapeutics · NCT05498389 · 115 planned · United States, China
  5. Dec 4, 2025Phase 2 study in Colorectal NeoplasmsShanghai EpimAb Biotherapeutics · NCT07314294 · 54 planned · China

Ahead

  1. Dec 30, 2027Primary completion: phase 2 study in Colorectal NeoplasmsShanghai EpimAb Biotherapeutics · NCT07314294

TargetBeta

EGFR →MET →read by rule
“A human, Fabs-in-tandem immunoglobulin (FIT-Ig)-based, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor EGFR and the hepatocyte growth factor receptor (HGFR; cMet; c-Met), ”NCIt, by rule
“Hepatocyte growth factor receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
amivantamabruleJohnson & Johnsonphase 316
HS-20117Hansoh Pharmaceutical Groupphase 33
pamvatamigruleBetta Pharmaceuticalsphase 25
TQB2922Sino Biopharmaceuticalphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07314294Colorectal Neoplasms · China2RecruitingShanghai EpimAb BiotherapeuticsDec 30, 202754
NCT05498389Carcinoma, Non-Small-Cell Lung · United States, China2Not yet recruitingShanghai EpimAb BiotherapeuticsJul 2024115
NCT05176665Neoplasms · United States, China2RecruitingShanghai EpimAb BiotherapeuticsDec 31, 2025152
NCT04868253Smoking Cessation · United States3UNKNOWNRose Research CenterDec 31, 202125
NCT03797391Neoplasms · United States, China2RecruitingShanghai EpimAb BiotherapeuticsMar 14, 2025186

How it is read

Names in the registry

  • “EMB-01”, 4 entries
  • “EMB-01 1600 mg administered once weekly throughout the study”, 1 entry
  • “EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.